Comparison of Four T-cell Assays and Two Binding Antibody Assays in SARS-CoV-2 Vaccinees With or Without Omicron Breakthrough Infection
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Several T-cell response assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are available; however, their comparability and correlations with antibody responses remain unclear. We compared four SARS-CoV-2 T-cell response assays and two anti-SARS-CoV-2 spike antibody assays. Methods: We enrolled 89 participants who had received a booster dose of the BNT162b2 vaccine after two doses of the ChAdOx1 or BNT162b2 vaccine. Fifty-six participants without breakthrough infection (BI) (ChAdOx1/BNT162b2 group: N=27; BNT162b2 group: N=29) and 33 with BI were included. We evaluated two whole-blood interferon-gamma release assays (IGRAs) (QuantiFERON and Euroimmun), T-SPOT.COVID, an in-house enzyme-linked immunospot (ELISPOT) assay (targeting the spike and nucleocapsid peptides of wild-type and Omicron SARS-CoV-2), Abbott IgG II Quant, and Elecsys Anti-S, using Mann–Whitney U, Wilcoxon signed-rank, and Spearman’s correlation tests. Results: The correlations between the IGRAs and between the ELISPOT assays (ρ=0.60–0.70) were stronger than those between the IGRAs and ELISPOT assays (ρ=0.33–0.57). T-SPOT.COVID showed a strong correlation with Omicron ELISPOT (ρ=0.70). The anti-spike antibody assays showed moderate correlations with T-SPOT.COVID, Euroimmun IGRA, and ELISPOT (ρ=0.43–0.62). Correlations tended to be higher in the BI than in the noninfected group, indicating that infection induces a stronger immune response. Conclusions: T-cell response assays show moderate to strong correlations, particularly when using the same platform. T-SPOT.COVID exhibits potential for estimating immune responses to the Omicron variant. To accurately define SARS-CoV-2 immune status, both T-cell and B-cell response measurements are necessary.
Abstract
Background: Several T-cell response assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are available; however, their comparability and correlations with antibody responses remain unclear. We compared four SARS-CoV-2 T-cell response assays and two anti-SARS-CoV-2 spike antibody assays. Methods: We enrolled 89 participants who had received a booster dose of the BNT162b2 vaccine after two doses of the ChAdOx1 or BNT162b2 vaccine. Fifty-six participants without breakthrough infection (BI) (ChAdOx1/BNT162b2 group: N=27; BNT162b2 group: N=29) and 33 with BI were included. We evaluated two whole-blood interferon-gamma release assays (IGRAs) (QuantiFERON and Euroimmun), T-SPOT.COVID, an in-house enzyme-linked immunospot (ELISPOT) assay (targeting the spike and nucleocapsid peptides of wild-type and Omicron SARS-CoV-2), Abbott IgG II Quant, and Elecsys Anti-S, using Mann–Whitney U, Wilcoxon signed-rank, and Spearman’s correlation tests. Results: The correlations between the IGRAs and between the ELISPOT assays (ρ=0.60–0.70) were stronger than those between the IGRAs and ELISPOT assays (ρ=0.33–0.57). T-SPOT.COVID showed a strong correlation with Omicron ELISPOT (ρ=0.70). The anti-spike antibody assays showed moderate correlations with T-SPOT.COVID, Euroimmun IGRA, and ELISPOT (ρ=0.43–0.62). Correlations tended to be higher in the BI than in the noninfected group, indicating that infection induces a stronger immune response. Conclusions: T-cell response assays show moderate to strong correlations, particularly when using the same platform. T-SPOT.COVID exhibits potential for estimating immune responses to the Omicron variant. To accurately define SARS-CoV-2 immune status, both T-cell and B-cell response measurements are necessary.
참고문헌 (32)
- "The coronavirus (COVID-19) dashboard" (2023)[URL]
- "Korea Disease and Control and Prevention Agency. COVID-19 vaccination" (2023)[URL]
- Planas D, "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization", Nature, 602, pp.671~675 (2022)
- Liu L, "Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2", Nature, 602, pp.676~681 (2022)
- GeurtsvanKessel CH, "Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients", Sci Immunol, 7, pp.eabo2202~ (2022)
- Basile K, "Improved neutralisation of the SARS-CoV-2 Omicron variant following a booster dose of Pfizer-BioNTech(BNT162b2)COVID-19 vaccine", Viruses, 14, pp.2023~ (2022)
- Liu J, "Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron", Nature, 603, pp.493~496 (2022)
- Gao Y, "Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant", Nat Med, 28, pp.472~476 (2022)
- Zuo J, "Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection", Nat Immunol, 22, pp.620~626 (2021)
- Le Bert N, "Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men", Emerg Microbes Infect, 10, pp.2141~2150 (2021)
- Bonnet B, "Decline of humoral and cellular immune responses against SARS-CoV-2 6 months after full BNT162b2 vaccination in hospital healthcare workers", Front Immunol, 13, pp.842912~ (2022)
- Naranbhai V, "T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals", Cell, 185, pp.1041~1051 (2022)
- Brand I, "Broad T cell targeting of structural proteins after SARS-CoV-2 infection : high throughput assessment of T cell reactivity using an automated interferon gamma release assay", Front Immunol, 12, pp.688436~ (2021)
- Taus E, "Dominant CD8+ T cell nucleocapsid targeting in SARS-CoV-2 infection and broad spike targeting from vaccination", Front Immunol, 13, pp.835830~ (2022)
- Woldemeskel BA, "SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge", JCI Insight, pp.e159474~ (2022)
- Uwamino Y, "Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine", Vaccine, 40, pp.4538~4543 (2022)
- Kim JY, "Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural coronavirus disease 2019 infections over a 3-month period", J Infect Dis, 225, pp.777~784 (2022)
- Strengert M, "Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis", EBioMedicine, 70, pp.103524~ (2021)
- Malipiero G, "Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease", Immunol Res, 69, pp.576~583 (2021)
- Safont G, "Measuring T-cell responses against SARS-CoV-2 is of utility for disease and vaccination management", J Clin Med, 11, pp.5103~ (2022)
- Primorac D, "Cellular immunity-the key to long-term protection in individuals recovered from SARS-CoV-2 and after vaccination", Vaccines(Basel), 10, pp.442~ (2022)
- Hillus D, "Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study", Lancet Respir Med, 9, pp.1255~1265 (2021)
- Parry H, "Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people", Immun Ageing, 18, pp.34~ (2021)
- Schiffner J, "Long-term course of humoral and cellular immune responses in outpatients after SARS-CoV-2 infection", Front Public Health, 9, pp.732787~ (2021)
- Wongpakaran N, "A comparison of Cohen’s Kappa and Gwet’s AC1 when calculating inter-rater reliability coefficients : a study conducted with personality disorder samples", BMC Med Res Methodol, 13, pp.61~ (2013)
- Gwet KL, "Testing the difference of correlated agreement coefficients for statistical significance", Educ Psychol Meas, 76, pp.609~637 (2016)
- Altman DG, "Practical statistics for medical research", pp.404~ (1991), Chapman & Hall
- Salkind NJ, "Statistics for people who hate statistics", pp.132~ (2008), Sage Publications
- Schmidt F, "Plasma neutralization of the SARS-CoV-2 Omicron variant", N Engl J Med, 386, pp.599~601 (2022)
- Tarke A, "SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron", Cell, 185, pp.847~859 (2022)
- Bertoletti A, "SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic", Immunity, 55, pp.1764~1778 (2022)
- Kim Jung-Ah, "Immunogenicity of Third-dose BNT162b2 mRNA Vaccine Following Two Doses of ChAdOx1 in Health Care Workers: A Prospective Longitudinal Study", Annals of Laboratory Medicine, 42(6), pp.688~692 (2022), 대한진단검사의학회[DOI]